Lexaria Bioscience Corp. (LEXX) stock
LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày May 31, 2026Last filing: 10-Q on Jul 13, 2026Score 8/30
$4.28+0.10 (+2.39%)
Close on Nov 18, 2026Market cap $106.09MP/E –Yield –
Lexaria Bioscience operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Lexaria Bioscience's operating cash flow for the twelve months ending May 31, 2026 was -$7.43M. For fiscal 2025 it was -$10.45M. The highest annual figure on record is $321.00K in fiscal 2013.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | -$10.45M | – |
| FY2024 | Aug 31, 2024 | -$4.96M | – |
| FY2023 | Aug 31, 2023 | -$5.88M | – |
| FY2022 | Aug 31, 2022 | -$4.88M | – |
| FY2021 | Aug 31, 2021 | -$3.99M | – |
| FY2020 | Aug 31, 2020 | -$2.62M | – |
| FY2019 | Aug 31, 2019 | -$3.01M | – |
| FY2018 | Aug 31, 2018 | -$2.52M | – |
| FY2017 | Aug 31, 2017 | -$1.55M | – |
| FY2016 | Aug 31, 2016 | -$660.86K | – |
| FY2015 | Aug 31, 2015 | -$1.50M | -567.6% |
| FY2013 | Oct 31, 2013 | $321.00K | +136.1% |
| FY2012 | Oct 31, 2012 | $135.94K | +23.8% |
| FY2011 | Oct 31, 2011 | $109.84K | – |
| FY2010 | Oct 31, 2010 | -$330.34K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | May 31, 2026 | -$1.64M | – |
| Q2 FY2026CQ1 2026 | Feb 28, 2026 | -$2.16M | – |
| Q1 FY2026CQ4 2025 | Nov 30, 2025 | -$984.10K | – |
| Q4 FY2025CQ3 2025 | Aug 31, 2025 | -$2.64M | – |
| Q3 FY2025CQ2 2025 | May 31, 2025 | -$3.58M | – |
| Q2 FY2025CQ1 2025 | Feb 28, 2025 | -$1.50M | – |
| Q1 FY2025CQ4 2024 | Nov 30, 2024 | -$2.73M | – |
| Q4 FY2024CQ3 2024 | Aug 31, 2024 | -$1.89M | – |
| Q3 FY2024CQ2 2024 | May 31, 2024 | -$1.27M | – |
| Q2 FY2024CQ1 2024 | Feb 29, 2024 | -$619.61K | – |
| Q1 FY2024CQ4 2023 | Nov 30, 2023 | -$1.18M | – |
| Q4 FY2023CQ3 2023 | Aug 31, 2023 | -$1.62M | – |
| Q3 FY2023CQ2 2023 | May 31, 2023 | -$1.79M | – |
| Q2 FY2023CQ1 2023 | Feb 28, 2023 | -$1.23M | – |
| Q1 FY2023CQ4 2022 | Nov 30, 2022 | -$1.25M | – |
| Q4 FY2022CQ3 2022 | Aug 31, 2022 | -$1.18M | – |
| Q3 FY2022CQ2 2022 | May 31, 2022 | -$1.26M | – |
| Q2 FY2022CQ1 2022 | Feb 28, 2022 | -$1.28M | – |
| Q1 FY2022CQ4 2021 | Nov 30, 2021 | -$1.17M | – |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | -$1.11M | – |
| Q3 FY2021CQ2 2021 | May 31, 2021 | -$1.16M | – |
| Q2 FY2021CQ1 2021 | Feb 28, 2021 | -$911.25K | – |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | -$809.53K | – |
| Q4 FY2020CQ3 2020 | Aug 31, 2020 | -$639.35K | – |
| Q3 FY2020CQ2 2020 | May 31, 2020 | -$670.48K | – |
| Q2 FY2020CQ1 2020 | Feb 29, 2020 | -$753.88K | – |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | -$555.08K | – |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | -$736.61K | – |
| Q3 FY2019CQ2 2019 | May 31, 2019 | -$1.10M | – |
| Q2 FY2019CQ1 2019 | Feb 28, 2019 | -$603.26K | – |
| Q1 FY2019CQ4 2018 | Nov 30, 2018 | -$564.31K | – |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | -$837.06K | – |
| Q3 FY2018CQ2 2018 | May 31, 2018 | -$559.73K | – |
| Q2 FY2018CQ1 2018 | Feb 28, 2018 | -$600.87K | – |
| Q1 FY2018CQ4 2017 | Nov 30, 2017 | -$520.32K | – |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | -$353.34K | – |
| Q3 FY2017CQ2 2017 | May 31, 2017 | -$603.50K | – |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | -$488.09K | – |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | -$100.99K | – |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | -$260.77K | – |
See a number that looks wrong?